close

New IMI project “COMBINE” launched to accelerate the fight against antimicrobial resistance

Copenhagen, Denmark — December 3, 2019. 11 European partners today announced that they are launching a new project, The Collaboration for Prevention and Treatment of Multi-Drug Resistant Bacterial Infections (COMBINE), under the IMI AMR Accelerator Programme. COMBINE will support projects in the AMR Accelerator with effective management, communication, and data capture capabilities, and carry out research to strengthen the scientific basis in the AMR field. COMBINE is funded by IMI, a joint initiative between the European Commission (EC) and the European Federation of Pharmaceutical Industries and Associations (EFPIA). COMBINE receives EUR 8 million from the EC; EFPIA in-kind contributions total EUR 17 million.


The AMR Accelerator is a Public-Private Partnership initiated by IMI. With a total budget of EUR 295 million, six consortia aim to progress a pipeline of potential medicines targeting tuberculosis (TB), nontuberculous mycobacteria (NTM), Gram-positive and Gram-negative bacteria. If successful, the projects in the AMR Accelerator are expected to deliver up to 10 new preclinical candidates and up to 5 ‘Phase II-ready’ compounds over a six-year period. 



COMBINE will support the projects in the AMR Accelerator with effective management, and work to establish data management guidelines, improve and standardise animal infection models and facilitate optimised design for new clinical trials. To achieve these objectives, 11 partners with expertise in the field of antibiotic resistance from seven European countries have joined forces:  4 European academic partners (Uppsala UniversityFraunhofer-GesellschaftPaul-Ehrlich-InstitutStatens Serum Institut), 4 small and medium-sized enterprises (AsclepiaBIOCOMgrit42BEAM Alliance) and 3 pharmaceutical companies (GSKEvotecJanssen Pharmaceutica N.V.). Their work will include the development of innovative methodology facilitating preclinical and clinical development through analyses of aggregated preclinical and clinical trial data and initiation of a database with protocols, reference strains and antibiotic compounds to be used for standardization of preclinical models.

 

We need a broad innovative antibiotic pipeline to address the increasing rate of antibiotic drug resistance. Impactful Public-Private Partnerships like the AMR Accelerator are critical for developing this pipeline – they allow the few remaining companies in the field to make the most of their limited resources and strengthen the ties between SMEs and big pharma”, said Graham Somers, IMI Portfolio Director at GSK.



To ensure the smooth operation of the AMR Accelerator, COMBINE will set up a Coordination and Support Office to provide support with project management, data management and communication. “A forward looking, responsive and synergy-focused management group is essential to support all individual projects, communicate results and link the AMR Accelerator to existing AMR drug development initiatives”, said Anders Karlén, Professor at Uppsala University and Coordinator of COMBINE. 

Co-founder and CEO of grit42, Claus Stie Kallesøe, adds, “The COMBINE project is an important milestone in the evolution of grit42, as we'll be part of IMI's core AMR team and thus have a central role in the global fight against the antimicrobial resistance challenges. In addition, I also see this as an important validation of our company’s abilities and the strengths of our platform - assets we aim to leverage across the global AMR community, moving forward."



The discovery of antibiotics was one of the greatest and most valuable scientific and public health achievements of the 20th century. The AMR Accelerator has been initiated to help continue this achievement and to progress a pipeline of potential new medicines to treat and prevent infections caused by resistant bacteria.   



About the Innovative Medicines Initiative

The Innovative Medicines Initiative (IMI) is working to improve health by speeding up the development of, and patient access to, the next generation of medicines, particularly in areas where there is an unmet medical or social need. It does this by facilitating collaboration between the key players involved in healthcare research, including universities, pharmaceutical companies, and other companies active in healthcare research, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators. This approach has proven highly successful, and IMI projects are delivering exciting results that are helping to advance the development of urgently-needed new treatments in diverse areas.



IMI is a partnership between the European Union and the European pharmaceutical industry, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA).




About the AMR Accelerator

The aim of the IMI Antimicrobial Resistance (AMR) Accelerator is to progress the development of new medicines to treat or prevent resistant bacterial infections in Europe and worldwide. The programme comprises three pillars: a Capability Building Network, a Tuberculosis Drug Development Network; and Portfolio Building Networks. The scope of the AMR Accelerator is broad; under one structure, it addresses many of the scientific challenges of AMR, and it supports the development of new ways to prevent and treat AMR. More broadly, the IMI AMR Accelerator contributes to the European action plan on AMR. 

About grit42
Copenhagen-based grit42 focuses on integrating digital laboratory infrastructure with user-friendly day-to-day lab workflows, as well as handling compound and sample logistics, in order to ensure structured quality data across all the different pre-clinical drug discovery phases.
 
Contact grit42
Lasse H. Görlitz, head of communications

goerlitz@grit42.com 

TEL: +45 2758 2601